VANCOUVER, British Columbia, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Neutrisci International Inc. (the "Company" or
"NeutriSci") (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9) the innovator and pioneer behind neuenergy®, is
pleased to announce that it has received its first order for its sublingual cannabidiol (CBD) tablets. This initial order will
result in the Company reporting six figure sales for the current quarter. The quick dissolving, flavoured tablets are manufactured
using the Company’s patent pending technology and offer a method to provide the consumer with a measured dose of known CBD product.
NeutriSci CEO, Glen Rehman stated, “We have been working hard to bring several new product innovations to market through our
partnerships in the legal cannabis industry, and we are extremely happy to share this news with shareholders. The Company continues
to move forward with its product and distribution arrangements with its previously announced
partnerships.”
The Company continues to work on expanding its partnerships and distribution alliances within the cannabis industry and expects
to announce further growth and sales of its IP and product lines over the coming weeks and months.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Investor Relations
NeutriSci International Inc.
Tel: (403) 264-6320
Email: info@neutrisci.com
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in
2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for
neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of
blueberries.
Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally
derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no
calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.
For more information, please visit: www.neutrisci.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All
statements within, other than statements of historical fact, are to be considered forward looking. Although the Company
believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not
guarantees of future performance and actual results or developments may differ materially from those in forward-looking
statements. Factors that could cause actual results to differ materially from those in forward-looking statements include
market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic,
market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers
are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any
forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration.
Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
